Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats

Endocrinology

Volumn 145, Issue 7, 2004, Pages 3153-3157

  Young, Morag ^a   Funder, John W ^a  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; COLLAGEN; CYCLOOXYGENASE 2; DEOXYCORTICOSTERONE; EPLERENONE; MINERALOCORTICOID ANTAGONIST; OSTEOPONTIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SODIUM CHLORIDE; STEROID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY BLOOD VESSEL; DRINKING; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BLOCKING; SALT INTAKE; UNINEPHRECTOMY;

ANIMALS; BIOLOGICAL MARKERS; CORONARY VESSELS; DESOXYCORTICOSTERONE; FIBROSIS; MALE; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; RECEPTORS, MINERALOCORTICOID; SODIUM CHLORIDE, DIETARY; SPIRONOLACTONE; VASCULITIS;

EID: 3042647297     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/en.2004-0005     Document Type: Article

References (33)

1. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, Swynghedauw B, Delcayre C 1995 Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 26:971-978
2. Brilla CG, Weber KT 1992 Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120:893-901
3. Young M, Fullerton M, Dilley R, Funder J 1994 Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93:2578-2583
4. Brilla CG, Matsubara LS, Weber KT 1993 Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25:563-575
5. Young MJ, Funder JW 1996 The renin-angiotensin-aldosterone system in experimental mineralocorticoid-salt-induced cardiac fibrosis. Am J Physiol 271:E883-E888
6. Young MJ, Funder JW 1996 Mineralocorticoids, salt, hypertension: effects on the heart. Steroids 61:233-235
7. Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre C 1994 Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension 24:30-36
8. Campbell SE, Janicki JS, Weber KT 1995 Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol 27:1545-1560
9. Young MJ, Moussa L, Dilley R, Funder JW 2003 Early inflammatory responses in experimental cardiac hypertrophy and fibrosis: effects of 11β-hydroxysteroid dehydrogenase inactivation. Endocrinology 144:1121-1125
10. Fujisawa G, Dilley R, Fullerton MJ, Funder JW 2001 Experimental cardiac fibrosis: differential time course of responses to mineralocorticoid-salt administration. Endocrinology 142:3625-3631
11. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EA, McMahon EG, Delyani JA 2002 Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol 283:H1802-H1810
12. Rocha R, Chander PN, Khanna K, Zuckerman A, Stier Jr CT 1998 Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 31:451-458
13. Zannad F, Alla F, Dousset B, Perez A, Pitt B 2000 Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation 102:2700-2706
14. Suzuki G, Morita H, Mishima T, Sharov VG, Todor A, Tanheco EJ, Rudolph AE, McMahon EG, Goldstein S, Sabbah HN 2002 Effects of long-term monotherapy with eplerenone, a novel aldosterone blocker, on progression of left ventricular dysfunction and remodeling in dogs with heart failure. Circulation 106:2967-2972
15. Brown L, Duce B, Miric G, Sernia C 1999 Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J Am Soc Nephrol 10(Suppl 11):S143-S148
16. Ball AM, Sole MJ 1998 Oxidative stress and the pathogenesis of heart failure. Cardiol Clin 16:665-675, viii-ix
17. Jeremy JY, Yim AP, Wan S, Angelini GD 2002 Oxidative stress, nitric oxide, and vascular disease. J Card Surg 17:324-327
18. Kameda K, Matsunaga T, Abe N, Hanada H, Ishizaka H, Ono H, Saitoh M, Fukui K, Fukuda I, Osanai T, Okumura K 2003 Correlation of oxidative stress with activity of matrix metalloproteinase in patients with coronary artery disease. Possible role for left ventricular remodelling. Eur Heart J 24:2180-2185
19. Sorescu D, Griendling KK 2002 Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 8:132-140
20. phox homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88:888-894
21. phox is a critical component of the superoxide-generating NADH/NADPH oxidase system and regulates angiotensin II-induced hypertrophy in vascular smooth muscle cells. J Biol Chem 271:23317-23321
22. Sun Y, Zhang J, Lu L, Chen SS, Quinn MT, Weber KT 2002 Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol 161:1773-1781
23. Hamilton CA, Brosnan MJ, Al-Benna S, Berg G, Dominiczak AF 2002 NAD(P)H oxidase inhibition improves endothelial function in rat and human blood vessels. Hypertension 40:755-762
24. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M 2000 Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol 20:2175-2183
25. Li T, Danelisen I, Bello-Klein A, Singal PK 2000 Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res 46:523-530
26. phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 87:26-32
27. Alzamora R, Michea L, Marusic ET 2000 Role of 11β-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension 35:1099-1104
28. Young M, Funder J 2003 Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Endocrinology 144:3848-3851
29. Funder J, Myles K 1996 Exclusion of corticosterone from epithelial mineralocorticoid receptors is insufficient for selectivity of aldosterone action: in vivo binding studies. Endocrinology 137:5264-5268
30. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG 2003 Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 93:69-76
31. Ward MR, Kanellakis P, Ramsey D, Funder J, Bobik A 2001 Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation 104:467-472
32. Funder JW 2004 Is aldosterone bad for the heart? Trends Endocrinol Metab 15:139-142
33. Funder JW 2003 The role of mineralocorticoid receptor antagonists in the treatment of cardiac failure. Expert Opin Invest Drugs 12:1963-1969